A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT06315257
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PVX7 — DRUG
    PVX7 Immunotherapy

Study Details

A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.

Key Dates

Start date
Jul 23, 2025
Status verified
May 2026
Primary completion
Feb 28, 2030
Completion
Apr 30, 2032

Study Design

Enrollment
32 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: pBI-11 DNA plus TA-HPV via Skin Inoculation
    Participants will receive pBI-11 DNA by IM injection and TA-HPV via Skin Inoculation
  • Experimental: pBI-11 DNA plus TA-HPV via IM Injection
    Participants will receive pBI-11 DNA and TA-HPV via IM Injection

Primary Outcome Measure

Safety of PVX7 as assessed by adverse events [ Time Frame: 12 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
The University of Alabama at BirminghamBirminghamAlabama35233
Anna Wilbanks, Research Nurse, MSN, RN, WHNP-BC
[email protected]
205-996-7079
Charles Leath, MD (PRINCIPAL_INVESTIGATOR)
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21287
Amy Deery, RN, BSN, OCN
[email protected]
410-614-1361
Stéphanie Gaillard, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

By condition
Cervical cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
The University of Alabama at Birmingham· Birmingham, ALSidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Baltimore, MD

Related Studies